Seeking Alpha

BioNTech to acquire Neon Therapeutics in all-stock deal

|About: BioNTech SE (BNTX)|By: , SA News Editor

BioNTech SE (NASDAQ:BNTX) has agreed to acquire Neon Therapeutics (NASDAQ:NTGN) in an all-stock transaction valued at ~$67M ($2.18/share). Under the terms of the deal, Neon shareholders will receive 0.063 of a BNTX ADS for each NEON common share held.

Neon's lead candidate is NEO-PTC-01, a personalized neoantigen-targeted T cell therapy.

Try Seeking Alpha PREMIUM for unlimited analysis on BNTX